Domestic anti-neocoronazole potent drugs are generally referred to as Ambavizumab/Romivizumab combination therapy, which is injected into the body and takes effect immediately. Ambavirizumab/Romivirizumab combination therapy potent drug received marketing approval from the Chinese Drug Administration. According to experts, the drug is injected intravenously and the whole process takes about 40 minutes. It takes effect immediately after injection and provides the body with a strong protective effect. The drug is a monoclonal neutralizing antibody obtained from patients recovering from a novel coronavirus pneumonia, with special application of bioengineering techniques to reduce the risk of antibody-mediated dependent potentiation and to prolong the plasma half-life for a longer-lasting therapeutic effect. Although the new drug has been approved for marketing, there is no exact time frame for its full introduction to the market. [Note: In this article, the terms “neocoronavirus pneumonia and novel coronavirus pneumonia” were renamed to “novel coronavirus infection” on December 26, 2022, as announced by the National Health Commission.